ArrowMark Colorado Holdings’s Apogee Therapeutics APGE Stock Holding History

ArrowMark Colorado Holdings’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-109,410	Closed	-$9.21M	–	298
2026 Q1	$9.21M	Hold	109,410	–	–	0.24%	124
2025 Q4	$8.26M	Hold	109,410	–	–	0.18%	155
2025 Q3	$4.35M	Hold	109,410	–	–	0.08%	202
2025 Q2	$4.75M	Hold	109,410	–	–	0.09%	189
2025 Q1	$4.09M	Hold	109,410	–	–	0.07%	189
2024 Q4	$4.96M	Hold	109,410	–	–	0.07%	191
2024 Q3	$6.43M	Hold	109,410	–	–	0.08%	168
2024 Q2	$4.31M	Hold	109,410	–	–	0.05%	214
2024 Q1	$7.27M	Buy	109,410 +30,000	+38%	+$1.31M	0.08%	178
2023 Q4	$2.22M	Hold	79,410	–	–	0.02%	236
2023 Q3	$1.69M	Buy	+79,410	New	+$1.75M	0.02%	242

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

ArrowMark Colorado Holdings's APGE Position: Q2 2026 in Review

ArrowMark Colorado Holdings sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 109,410 shares — an estimated $9.21M sold.

ArrowMark Colorado Holdings first reported a position in APGE in Q3 2023 and held it in 11 quarters. The position peaked at $9.21M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

ArrowMark Colorado Holdings reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
ArrowMark Colorado Holdings sold 109,410 Apogee Therapeutics shares in Q2 2026, an estimated $9.21M.
ArrowMark Colorado Holdings first reported a position in Apogee Therapeutics in Q3 2023 and held it in 11 quarters.
ArrowMark Colorado Holdings's Apogee Therapeutics position peaked at $9.21M in Q1 2026.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.